KLOW
KLOW is a single premixed vial combining BPC-157, TB-500, KPV, and GHK-Cu (80 mg total in 3 mL) for recovery, skin, and immune support; research protocols dose by insulin units, starting around 10 units and building toward 30 units (about 5 mg GHK-Cu/day) subcutaneously.
Adults seeking combined connective-tissue recovery, skin and hair support, and anti-inflammatory signaling in one multi-peptide vial. Because it contains four active peptides, it is not recommended as a first-time peptide protocol; physician guidance is advised.
KLOW is a single premixed vial combining four research-grade peptides — BPC-157 (10 mg), TB-500 (10 mg), KPV (10 mg), and GHK-Cu (50 mg), for 80 mg total in 3 mL — built to cover recovery, skin, and immune pathways at once. BPC-157 is a 15-amino-acid pentadecapeptide derived from a protective protein found in gastric juice; research suggests it supports angiogenesis (new blood-vessel formation in injured tissue), modulates growth-factor pathways including FGF and VEGF, and accelerates tendon-to-bone healing in animal models, acting primarily at the local injury site. TB-500, a synthetic version of Thymosin Beta-4, is a 43-amino-acid peptide present in nearly every nucleated human cell and a major regulator of actin polymerization and cell migration; it promotes systemic cellular migration and recruitment of repair cells from distant sites.
Pairing local repair (BPC-157) with systemic migration (TB-500) is the classic complementary recovery stack. KPV, a Lys-Pro-Val tripeptide and C-terminal fragment of alpha-MSH, has documented anti-inflammatory effects via NF-κB pathway modulation. GHK-Cu, a Gly-His-Lys copper-peptide complex, is studied for collagen synthesis, skin quality, and hair-follicle health; the copper can sting at the injection site, so let the filled syringe reach room temperature (about 20 minutes) and inject slowly.
None of these peptides is FDA-approved for human use, so this is strictly a research-context blend; because it combines four active peptides it is not a first-time protocol and physician guidance is advised. Each batch is independently lab-tested for identity and purity across all four components per our standard COA process.
Subcutaneous injection, dosed by insulin units rather than milligrams because it is a multi-peptide blend (80 mg total in 3 mL). A common research-context approach starts at roughly 10 units and builds toward roughly 30 units (about 5 mg GHK-Cu per day) toward the target dose. Localized-heal eligible: it can be injected near a target site instead of rotating the usual systemic sites. GHK-Cu (copper) can sting at the injection site — after drawing your dose, set the filled syringe on the counter for about 20 minutes to reach room temperature, then inject slowly. Specific dosing varies by goal and physician guidance.
Multi-system effects (recovery, skin, inflammation) typically develop over several weeks of consistent daily use, consistent with its individual components. Timelines vary by individual and goal.
Built as a broad standalone stack — its four components already cover local repair, systemic migration, anti-inflammatory signaling, and skin/collagen support, so additional peptides are usually redundant for these goals.
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.